Mesenchymal stromal cells (MSCs) have been extensively investigated as a potential antiinflammatory treatment in many inflammatory-related diseases; however, it remains unclear whether MSCs could be used to treat acute allergic rhinitis. A rat model of allergic rhinitis was treated with MSCs. The effect of MSCs on the inflammation of allergic rhinitis was evaluated by sneezing, nose rubbing, the pathology of the nasal mucosa, and the expression of interleukin 4, tumour necrosis factor alpha, and immunoglobulin E in the serum of rats. Also, the population of MSCs isolated from umbilical cords of humans was evaluated to determine if they could inhibit the symptoms and inflammation of acute allergic rhinitis in a rat model. We observed that this population of cells inhibited sneezing, nose rubbing, and changes in the pathology of the nasal mucosa. Intriguingly, we observed that MSCs reduced the expression of interleukin 4, tumour necrosis factor alpha, and immunoglobulin E in the serum. Furthermore, MSCs reduced the expression of histamine and the recruitment of macrophages in the nasal mucosa of allergic rhinitis rats. We reasoned that the effect of MSCs on allergic rhinitis might be through its regulation of the secretion of related cytokines from macrophages during the process of acute allergic rhinitis. This work suggested that MSCs from the umbilical cords of humans could be used as a positive clinical therapy for the human disease.
Mesenchymal stromal cells (MSCs) have been extensively investigated as a potential antiinflammatory treatment in many inflammatory-related diseases; however, it remains unclear whether MSCs could be used to treat acute allergic rhinitis. A rat model of allergic rhinitis was treated with MSCs. The effect of MSCs on the inflammation of allergic rhinitis was evaluated by sneezing, nose rubbing, the pathology of the nasal mucosa, and the expression of interleukin 4, tumour necrosis factor alpha, and immunoglobulin E in the serum of rats. Also, the population of MSCs isolated from umbilical cords of humans was evaluated to determine if they could inhibit the symptoms and inflammation of acute allergic rhinitis in a rat model. We observed that this population of cells inhibited sneezing, nose rubbing, and changes in the pathology of the nasal mucosa. Intriguingly, we observed that MSCs reduced the expression of interleukin 4, tumour necrosis factor alpha, and immunoglobulin E in the serum. Furthermore, MSCs reduced the expression of histamine and the recruitment of macrophages in the nasal mucosa of allergic rhinitis rats. We reasoned that the effect of MSCs on allergic rhinitis might be through its regulation of the secretion of related cytokines from macrophages during the process of acute allergic rhinitis. This work suggested that MSCs from the umbilical cords of humans could be used as a positive clinical therapy for the human disease. 1,2 Allergic rhinitis is a common health problem in both children and adults. Nearly 30% of the world population suffers from this disease. 3 The classical symptoms of AR include sneezing, rhinorrhoea, nasal itching, and congestion; multiple related symptoms may occur at the same time. 4 Although the symptoms resemble those of the common cold, they often last for more than 2 weeks and typically do not include a fever. 5 Patients who suffer from AR sustain a significant negative impact on their quality of life.
Allergic rhinitis is an immune disorder, and it is caused by hypersensitivity towards all kinds of allergens. suppresses Th1 and Th17 cell responses through the upregulation of transcriptional repressors of interferon gamma (IFN-γ) and IL17 that play important roles in the process of AR. 11, 12 Thus, the regulation of the disordered inflammatory cytokine secretion could be a potential strategy to cure AR.
Human mesenchymal stromal cells (MSCs) are multilineage stem cells that can be isolated from bone marrow, umbilical cord, amniotic membrane, fat aspirate, and dental pulp. 13 In recent years, this population of cells has been reported to inhibit inflammation as a promising therapeutic strategy to many inflammatory diseases and cancers [14] [15] [16] ; however, no study has been conducted to reveal the efficacy and possible mechanisms of human MSCs in the treatment of AR.
In the present study, we isolated MSCs from human umbilical cord and aimed to evaluate their effect on allergic inflammatory responses in an ovalbumin (OVA)-induced AR model in rats. Intriguingly, we observed that MSCs from human umbilical cord appear to have significant therapeutic efficacy in inhibiting the symptoms of sneezing and nose rubbing in acute AR rats. We further analysed that the anti-AR effect of MSCs might be associated with the regulation of cytokine secretion from macrophages during the process of AR. Our study provides hope for the therapy of AR using MSCs from human umbilical cord.
| MATERIALS AND METHODS

| Cells
Mesenchymal stromal cells were isolated with high efficiency from umbilical cord under the agreement of informed consent in the hospital and expanded in vitro with Eagle's minimal essential medium (Gibco/ BRL, USA), supplemented with 10% foetal bovine serum and 1 × L-glutamine, according to the method reported by Izaskun Ferrin et al. 13 The Institution Review Board of Tsinghua University approved the entirety of the project and found it concurrent with all related protocols (no: 20170013).
| Rats
A total of 60 male Sprague-Dawley rats (160-180 g) were purchased
from Vital River Laboratories (Beijing, China 
| Ovalbumin-induced allergic rhinitis rat models
The rats were sensitized by OVA by using a standard protocol. Briefly, OVA and aluminium hydroxide gel diluted in normal saline (1 mg/ mL + 30 mg/mL + 1 mL) were used to sensitize the rats 3 times via 
| Evaluation of nasal symptoms
On the 30th day from the first injection of MSC cells, the rats were stimulated by the dropping of OVA (20 μL/nostril, 50 mg/mL) dissolved in a physiological saline solution into the bilateral nasal cavities, and maintained in the observation cage. Instances of sneezing and nose scratching were counted for 10 minutes after the OVA intranasal stimulation to evaluate the degree of allergic responses. The control rats were processed with saline.
| Histological analysis of nasal mucosa
7After the experiment, the rats were sacrificed by drawing out all the blood in the hearts after isoflurane anaesthesia, and the nasal mucosa was separated and fixed in 4% paraformaldehyde at room temperature. After fixation, the tissues were routinely paraffin embedded, sectioned at 4 μm thickness, and stained with haematoxylin and eosin to examine eosinophils, lesions, and swelling of the nasal mucosa.
| Serum and plasma
Abdominal aorta blood samples (at least 10 mL) were collected in vacutainer tubes under sterile conditions from the normal, model, and treatment groups of rats. Serum and plasma were obtained following rapid centrifugation and stored at −80°C. Figure 3B ). It appeared that all of the treatments had similar significant effects on the inhibition of the production of TNF-α. On the other hand, the levels of IL-17 and IFN-γ were not significantly changed after the MCS treatments, although IL-17 tended to decrease ( Figure 3C ) and INF-γ tended to increase slightly ( Figure 3D ). Together, these results indicate that MSCs play a role in the regulation of the production of inflammatory cytokines, in particular, IL-4 and TNF-α.
| Mesenchymal stromal cells reduce histamine in the plasma of allergic rhinitis rats
Antigen-induced IgE and histamine release from mast cell degranulation are the features of AR. 8, 10 To further examine the therapeutic effect of MSCs on AR, we measured the expression level of IgE in the serum and histamine in the plasma in each group of rats via ELISA.
Our results displayed that the multiple dosage treatment significantly decreased the level of IgE ( Figure 4A ) and inhibited histamine release caused by OVA stimulation in AR rats ( Figure 4B ). These results suggest that MSCs function in inhibiting mast cells, preventing them from secreting histamine. These results are consistent with the symptom amelioration of acute AR in rats.
| DISCUSSIONS
Allergic rhinitis is a common inflammatory disease worldwide. 1, 4, 5 Patients have a well-defined phenotype, including increased airway resistance, oral breathing difficulty, sleep disturbance, and problems with social activities. 2, 6 Current chemical drugs towards AR are limited to antihistamines, antiallergens, antileukotrienes, and intranasal corticosteroids that only alleviate allergic symptoms but fail to regulate the allergic reaction. Occasionally, these drugs have side effects, such as headache, throat irritation, and nasal dryness. [17] [18] [19] Thus, the development of more safe and effective therapeutic agents is needed.
Mesenchymal stromal cells have been proven to possess immunomodulatory and antiinflammatory properties. 20 Currently, human
MSCs hold great promise in regenerative medicine for the therapy of human diseases. [14] [15] [16] Human MCSs can be acquired from many tissues, such as umbilical cord, bone marrow, and chorionic membrane. The MSCs used in this study were isolated from human umbilical cord. The successful study of the pathogenesis and pathophysiology is dependent upon the establishment of a successful animal model of Quantification of the severity of the tissue damage using the standard histology scoring system. *P < .05, **P < .01, and ***P < .001
AR. Animal models induced by intraperitoneal injections of allergens vary greatly from the natural processes of AR. It has been reported that
MSCs mediate their immunomodulatory effects by interacting with adaptive immunity systems; an altered Th1/Th2 balance in allergic diathesis has recently been termed a "procrustean paradigm". 24 T
helper type 2 are activated by proinflammatory cytokines such as FIGURE 4 (A) Mesenchymal stromal cell (MCS) treatment 4 times after the establishment of ovalbumin (OVA)-induced acute allergic rhinitis in rats significantly attenuated the expression of immunoglobulin E (IgE) in the serum of the rats. (B) MCS treatment once before or 4 times after the establishment of OVA-induced acute allergic rhinitis in rats obviously reduced the expression of histamine in the serum of the rats. *P < .05, **P < .01, and ***P < .001 have no statistical significance between the OVA-induced acute allergic rhinitis rats and the MCS treatment groups, the results correspond with the prospective tendency. *P < .05, **P < .01, and ***P < .001
IL-4 that are produced in the process of AR. 25 The ability of MSCs to significantly decrease the secretion of IL-4 is the main reason why the injection of MSCs is effective in AR. Furthermore, macrophages are another key player in AR, and we found that MSCs achieve their antiinflammatory effects by reducing the secretion of TNF-α.
Here, we investigated the role of umbilical cord-derived human MSCs in AR. Based on our studies, MSCs present a promising immediate curative effect to the inflammatory reaction in AR rats. Both AR symptoms and AR-related inflammatory cytokines have been inhibited by the intraperitoneal injection of MSCs. Although the continuous weekly therapy of MSCs for 1 month presents the strongest effects of AR in rats, the specification of therapeutic frequency, the dosage of MSCs, and the potential mechanism still need to be investigated further. Additionally, MSC therapy in AR needs to undergo innovations and improvements to be a more effective and safer treatment option for AR patients in the future.
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